Kanada - Inggris - Health Canada

marcan pharmaceuticals inc - paliperidone - tablet (extended-release) - 3mg - paliperidone 3mg - atypical antipsychotics

Kanada - Inggris - Health Canada

marcan pharmaceuticals inc - paliperidone - tablet (extended-release) - 6mg - paliperidone 6mg - atypical antipsychotics

Kanada - Inggris - Health Canada

marcan pharmaceuticals inc - paliperidone - tablet (extended-release) - 9mg - paliperidone 9mg - atypical antipsychotics

Amerika Serikat - Inggris - NLM (National Library of Medicine)

remedyrepack inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)]. the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have bee

Amerika Serikat - Inggris - NLM (National Library of Medicine)

avera mckennan hospital - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

avera mckennan hospital - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 1.5 mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

american health packaging - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)]. the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)]. the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in pat

Amerika Serikat - Inggris - NLM (National Library of Medicine)

major pharmaceuticals - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.  paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated

Amerika Serikat - Inggris - NLM (National Library of Medicine)

tris pharma inc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in

Amerika Serikat - Inggris - NLM (National Library of Medicine)

archis pharma llc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaph